

# NCYPDN T2 Working Group Improving outcomes survey

Pooja Sachdev, Suma Uday, Anthony Walker, Heather Clark

#### Epidemiology – rising rates

- Increasing incidence
  - Zero (pre-2000)
  - 0.53/100,000 (2005)
  - 0.72/100,000 (2015)
  - 973 (NPDA 2020/21)
    - 12.4% increase; 23.6% new
  - 1144 (NPDA 2021/22)
    - 17.5% increase; 24.4% new

Prevalence of children living with obesity, living with severe obesity, overweight or living with obesity combined in Year 6, 2006/07 to 2021/22



<sup>\*</sup> Figures for 2020/21 are based on weighted data, see Methodology and Data Quality section in 2020/21 report for more information. For more information: Table 1b National Child Measurement Programme, England, 2021/22 School Year




## Diagnosis

#### No one criterion sensitive or specific:

- 85% had 3+ clinical / biochemical markers
  - Obesity (86%)
  - Acanthosis (51%)
  - Raised HbA1C (77%)
  - Absence of diabetes antibodies (40%)
  - Raised blood glucose (47%)

#### Diagnosis delayed 3 months of more:

- Less experienced PDUs,
- CYP without obesity,
- Higher HbA1C



#### Complications probably not treated well

Albuminuria in 26%

...But treated in 3.4% - further 7% "required treatment"

Almost 90% did not have liver ultrasounds

Where repeated, increasing proportion of fatty liver found

42% with raised BP

...But only 3.7% 24-ABPM and 6% offered antihypertensives

Only 8% lowered BMI category from diagnosis

Less likely to receive recommended health checks

# 2021/22 NPDA Key Findings – Type 2 diabetes


33%

of young people with T2D age 12+ with a complete year of care received all six key health checks in the audit year



46.1%

with T2D had high blood pressure (29.9 for T1DM)



48.3%

of CYP with T2D were assessed as requiring additional psychological or **CAMHS** support outside of MDT clinics, down from 59.5% in 2020/21

1144

children and young people with T2D were included in the audit, up from 963 in 2019/20



of young people with T2D had albuminuria compared to 11.5% of those with T<sub>1</sub>D

20.6%




#### Key messages from NPDA 2021/22


- 281 CYP newly diagnosed with T2DM (230 the previous year)
- Median HBA1C 50mmol/mol (53)
- Almost all (98.2 %) of those with T2DM were overweight or obese
- 8.4 %had an abnormal retinopathy screen (more than doubled)
- Cholesterol > 5 in 1/3rd

## Survey


- Period: December 2022-February 2023
- E-mail sent through NCYPDN Network Managers and T2
   National Working Group
- 109 responses received

#### Overall responses by hospital type (Four nations)







### Unit responses by Network / Region




#### Patient numbers by Network / Region




#### Where are CYP cared for – hospital type?




# Do you have a dedicated T2 diabetes clinic?





#### Do you have a dedicated T2 diabetes clinic?

Named discipline lead with special interest in T2, n=109



#### WNB/DNA policy for T2 diabetes


**Question:** What is your WNB/DNA policy for children and young people with type 2 diabetes? Is this different from those with type 1 and is it dependent on age?


- 92.6 % policy is similar
- However, in practice more likely to discharge older young people
- A third of 16-18 year olds are managed in primary care

### Cost of living and the impact on health

- According the RCPCH, the average cost of attending a clinic appointment is £35. Families report missing paediatric appointments because of the financial costs of attending due to travel, parking, food, childcare costs and potential loss of earnings, reported to be an average of £50
- Children living in poverty are more likely to have poorer health outcomes including low birth weight, poor physical health, and mental health problems
- The health impacts of growing up in poverty are significant and follow children across their life
- Children living in poverty are significantly more likely to suffer from acute and long term illness. They are significantly more likely to require hospital admission and 72% more likely than other children to be diagnosed with a long-term illness


## Admission at diagnosis (where no ambiguity)






#### Admission at diagnosis – qualitative findings





#### Do you recommend routine BG checks if not on insulin?




Additional free-text responses showed that the majority (17) recommended 1-2 tests per day; 12 recommended 2-4 tests per week and 13 did not specify frequency.

Several responses indicated the frequency depended on time since diagnosis and if the patient was unwell.


Four stated in line with ACDC.

Nine referenced recommending glucose monitoring.


#### Manual blood pressure measurements




### MDT able to initiate 24hr ambulatory BP monitoring?



#### Pathway for tertiary hypertension or renal referral




### Steps following a diagnosis of hypertension




## First line treatment for hypertension

No	66	ACE inhibitor (Unspecified)	11
Don't know	1	ACE inhibitor - specific one dependent on personal characteristics	3
Seek advice from specialist	8	Amlodipine	4
Lifestyle modification	1	Calcium channel blockers	1
Refer to national guidance	1	Enalapril	5
Would not initiate	1	Lisinopril	4
		Losartan	1
		Ramipril	2


#### Screening tool used for diagnosis of Obstructive Sleep Apnoea



# Sleep Apnoea screening and referral



### Dyslipidaemia screening at diagnosis




Most respondents reported that screening is conducted at diagnosis, then annually.


A small number of respondents clarified that screening took place after three months / at first clinic or when metabolic control was attained and annually thereafter.

Within both of the above, more frequent screening was carried out where results were abnormal.

#### What components of lipid profile were checked?





#### Guidelines on when to treat dyslipidaemia




Additional free-text comments for specifications on which guidelines were used	
ACDC	28
Other National/International Guidelines e.g. SPAD/OSCA/ADA/FH (inc. with ACDC)	9
Regional or Network data	2
Metabolic colleagues (Trust or Tertiary)	2
Unspecified / unsure	2
Biochemist	5
Developing own	2

### Screening for Non-Alcoholic Fatty Liver Disease





#### Referral pathway to a tertiary liver specialist team




#### Urinary Albumin to Creatinine ratio – measurement


#### Frequency:


108 responses stated urinary albumin to creatinine ratio was measured annually. One response stated this was done at each clinic visit

#### **Method:**



#### Elevated urinary Albumin to Creatinine ratio- action





#### Transition to adult care

#### Age of transition:

60% said transition starts at age 16

18% said 18-19 years

Small minority indicated 14-15 years, 17 years or dependant on age of the individual Some indicated that staffing/capacity issues had delayed when YP started transition

#### **Clinics:**

Majority indicated that transition process involved joint clinics.

One respondent advised of temporary discharge to GP due to a staffing gap

Three stated YP may be discharge to GP if DNA or by patient choice / stable.

#### Feedback on T2DM Guidelines

Concise insulindrug remissiontherapy

BG Revision new Co-morbidities
new Hub/spoke
reversal
update support

## Next steps

- Dissemination: National type 2 network meeting, DUK, National type 2 Study day, BSPED
- Review ACDC guidelines in light of barriers uncovered
- First year of care
- Develop care pathways to overcome barriers to screening and treatment of comorbidities
- Spotlight audit repeat?